H1N1 "Swine Flu" Vaccine Market Review (Revenues, Forecasts, Lessons for Future Pandemic Vaccines)
|出版日||ページ情報||英文 60 Pages
|H1N1「新型インフルエンザ」ワクチン市場のレビュー(収益・予測・将来の新型インフルエンザワクチンへの教訓) H1N1 "Swine Flu" Vaccine Market Review (Revenues, Forecasts, Lessons for Future Pandemic Vaccines)|
|出版日: 2010年05月01日||ページ情報: 英文 60 Pages||
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths.
Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and high publicity vaccine products? Kalorama has looked at vaccine products over the past decade and has seen the rise of interest in these products among pharmaceutical companies. While many suggest the H1N1 was a one time event, Kalorama believes there is something important to be gained in a market review of 2009 flu vaccine sales that will inform executives, investors and market watchers who are interested in the vaccine market.
This Kalorama Information report takes a detailed look at the H1N1 vaccine sales of 2009 based on available annual reports. Companies covered include AstraZeneca, Novartis, Glaxo and CSL among others. As part of its coverage, the report includes:
This Kalorama Information report was created as the result of both secondary and primary research. Research was conducted into the annual reports of major vaccine concerns, trade media coverage, company websites and medical and government literature. Interviews were used to make forecasts on the vaccine market and the influenza vaccine market for 2010-2014, which have been utilized in our estimate of the swine flu vaccine market impact for the 2010-2014 years. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources.